What drugs does OCULAR THERAPEUTIX make?

OCULAR THERAPEUTIX has 1 FDA-approved drugs including DEXTENZA.

What therapeutic areas does OCULAR THERAPEUTIX focus on?

OCULAR THERAPEUTIX focuses primarily on Ophthalmology and Cardiovascular.

← Back

Data updated: Mar 10, 2026

OCULAR THERAPEUTIX

OphthalmologyCardiovascular

Pharma

OCULAR THERAPEUTIX is a pharmaceutical company focused on Ophthalmology, Cardiovascular. Key products include DEXTENZA.

2018

Since

Drugs

Trials

Approved (2yr)

Key Drugs

DEXTENZA

dexamethasone

3 indications · 2018

Recent Activity

DEXTENZA 2025-04-07

Efficacy

SEC Filings ProEarly access

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Ophthalmology 78%

1 drugs Phase 3: 5 Phase 2: 4 Phase 1: 4

Cardiovascular 22%

0 drugs Phase 3: 2 Phase 2: 1 Phase 1: 1

Pipeline Strength ProEarly access

Competitors ProEarly access

Novartis big-pharma

Cardiovascular, Ophthalmology

Baxter specialty

Cardiovascular, Ophthalmology

Bayer big-pharma

Cardiovascular, Ophthalmology

B BRAUN specialty

Ophthalmology, Cardiovascular

BAUSCH specialty

Ophthalmology, Cardiovascular

OCULAR THERAPEUTIX

Key Drugs

Recent Activity

Therapeutic Focus

Pipeline Strength ProEarly access

Competitors ProEarly access

All Drugs (1)

Active (1)

Discontinued (0)

Company Info